Related Experiment Videos
Analysis of p16 gene deletion and point mutation in breast carcinoma
B Quesnel1, P Fenaux, N Philippe
1U124 Inserm Institut de Recherches sur le Cancer, Lille, France.
Abstract:
We looked for p16 gene deletion by Southern analysis and p16 gene point mutation by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing of DNA from fresh tumour samples of 35 and 33 breast carcinomas respectively. No homozygous p16 gene deletion was found in any case. A missense point mutation of the p16 gene was found in only one patient. This point mutation was absent from the patient's lymphocytes, ruling out a polymorphism or a germline mutation. These findings suggest that p16 gene alterations are rarely observed in breast carcinoma.
Insights
Alterations in the p16 gene are uncommon in breast cancer. Researchers found no p16 gene deletions and only one mutation in breast carcinoma samples, suggesting rare involvement of this gene in the disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p16 gene (also known as CDKN2A) is a tumor suppressor gene.
- Alterations in tumor suppressor genes are frequently implicated in cancer development.
- The role of p16 gene alterations in breast carcinoma requires further investigation.
Purpose of the Study:
- To investigate the frequency of p16 gene deletion and point mutations in breast carcinoma.
- To determine if p16 gene alterations are a common event in breast cancer pathogenesis.
Main Methods:
- Southern analysis was used to detect p16 gene deletions.
- Single-strand conformation polymorphism (SSCP) analysis and direct sequencing were employed to identify p16 gene point mutations.
- DNA was analyzed from fresh tumor samples of 35 breast carcinomas for deletions and 33 for point mutations.
Main Results:
- No homozygous deletions of the p16 gene were detected in any of the 35 breast carcinoma samples.
- A single missense point mutation in the p16 gene was identified in one of the 33 breast carcinoma samples analyzed.
- This identified point mutation was confirmed to be somatic, as it was absent in the patient's lymphocytes.
Conclusions:
- p16 gene alterations, including deletions and point mutations, appear to be rare events in breast carcinoma.
- These findings suggest that the p16 gene is not frequently altered in the development of breast cancer.
- Further research may be needed to explore other potential mechanisms of p16 pathway dysregulation in this disease.